Amgen announced the United States Food and Drug Administration (FDA) approval of AMJEVITA™ for treating adults with plaque psoriasis and psoriatic arthritis. AMJEVITA™ is a biosimilar to Humira® and the first of several other biosimilars expected to be approved later this year. AMJEVITA is citrate-free and will be available in prefilled syringe and autoinjector presentations.
This announcement follows the September 2022 approval from the U.S. Food and Drug Administration (FDA) and the Japan’s Ministry of Health, Labour, and Welfare.
European Commission grants conditional marketing authorization based on the EFFISAYIL® 1 trial, which showed over half of the spesolimab-treated patients were free of pustules, one week after receiving a single dose. This decision builds on existing approvals in the United States and Japan.
The International Psoriasis Council (IPC) and Scientific Education Support (SES) are excited to announce a strategic collaboration aimed to improve awareness, knowledge, and understanding of psoriasis, psoriatic arthritis, and other related diseases.
